The Textbook of Kidney Cancer
Springer London Ltd (Verlag)
978-1-84882-697-7 (ISBN)
- Titel wird leider nicht erscheinen
- Artikel merken
The main purpose of this book is to produce a fully comprehensive textbook of the whole subject of kidney cancer, providing theoretical and practical knowledge for both the basic researcher and also the clinical practitioner. In this way, the hope is to produce the definitive text in the field, wherein the theoretical basis of molecular, genetic, and patho-physiologic aspects will precede the practical aspects of surgical and medical-oncologic therapy. Unquestionably, at the time of writing, the contemporary management of kidney cancer is a hot topic in urologic oncology and it is this constantly evolving landscape which is the primary driving force underpinning the writing of this project now. Contemporary clinical management of patients with kidney cancer requires a clear understanding of these newly-emerged issues. Urologists, medical oncologists, and general practitioners are likely to welcome a comprehensive textbook that places the state-of-the-art of this field in context, within one volume. Ultimately, the book will be along the lines of "Campbell's Urology", aka 'the Bible of Urology', which is still relevant decades after its original publication.
Furthermore, the book will be innovatively designed and arranged, using many color illustrations and figures to augment the text of each chapter, thus providing a less daunting and more readable work. Similarly, the intended format is such that all key points in the text will be highlighted in the left-hand column of each page, for ease of topic summary and overview. In conjunction with the range of highlighted phrases and bulleted tables accompanying every chapter, the general presentation will constantly assist the reader in quickly recognizing the salient points of each specific topic at hand.
Preface.-History of renal cancer - David Bloom (Michigan) .-Epidemiology and Screening - Joseph K McLaughlin .-Renal Anatomy & Embryology - John Redman (Arkansas) .-Renal Physiology - Martin Schreiber (Cleveland) .-Renal Histology -???.-Pathology: Non-RCC - Eyas M. Hattab (Indiana) .-Pathology: Clear cell - Zhou (CCF), Victor Reuter (NYC) .-Pathology: Non-clear cell (papillar 1 & 2, chromophobe, etc) - Maria Marino (NCI) .-Hypoxia & HIF-related pathways - William Kaelin (Harvard) .-PTEN/mTOR/NFkB pathways - Pantuck (UCLA) .-Tuberous Sclerosis complex (TSC) - Brugarolis (Harvard) .-Familial syndromes - Marston Linehan (NCI) .-VHL mutations - Othon Iliopoulos (Boston) .-Mechanisms of Immunosuppression: Arginase - Ochoa (LSU) .-Mechanisms of Immunosuppression: B7H1, B7H4 - Eugene Kwon (Mayo) .-Mechanisms of Immunosuppression:Immune dysfunction & Tregs - Jim Finke (Cleveland) .-Molecular Genomics - Ben Teh .-Staging systems - Arie Belldegrun (UCLA) .-Prognostic Factors - Chris Wood (Houston) .-Biomarkers: Early detection - Othon Iliopolous (Boston) .-Biomarkers: Prognostic - Fray Marshall (Emory) .-Biomarkers: Expression Profiling - Liberman (Boston) .-Nomograms - Mike Kattan (Cleveland) .-Cystic RCC - Steve Campbell (Cleveland) .-Imaging : Ultrasonography - Jean de la Rosette (Amsterdam) .-Imaging: CT - Ramen (UCLA) .-Imaging: MRI - Rofsky, Pedrosa (Boston) .-Imaging: PET - Shetal Shah (Cleveland) .-Imaging: G250 Monoclonal Antibody - Osterwig (Netherlands) .-Augmented Reality - Osamu Ukimura (Kyoto, Japan) .-Paraneoplastic syndromes - ???? .-Needle Biopsy: current status - Samir Taneja (NYU) .-Pathology of renal biopsy for RCC - Laura Barisoni (NYU) .-Rationale for nephron-sparing - Paul Russo (MSKCC) .-Active surveillance: Pro - Uzzo/Jewett (Fox Chase/Toronto) .-Active Surveillance: Con - Michael Marberger (Austria) .-Open partial nephrectomy: USA - Andrew Novick (Cleveland) .-Open partial nephrectomy: Europe - Joachim Thuroff (Mainz) .-Open partial nephrectomy: non-clamping techniques - Arie Belldegrun (Los Angeles) .-Laparoscopic partial nephrectomy: basics - Ralph Clayman (Irvine) .-Laparoscopic partial nephrectomy: advanced - Inderbir Gill (Cleveland) .-Partial nephrectomy: Extended indications - Bradley Leibovitch (Mayo) .-Complications of partial nephrectomy: open and laparoscopic - Louis Kavoussi (New York) .-Biologic hemostatics and adhesives - Marshall Stoller (San Francisco) .-Renal hypothermia: Basic evidence and contemporary practice - Arieh Shalhav (Chicago) .-Renal cryotherapy: the basics - Steve Nakada (Wisconsin) .-Renal cryotherapy: current status - Inderbir Gill (Cleveland) .-Renal radiofrequency ablation: the basics - Jeffrey Caddedu (Dallas) .-Renal radiofrequency ablation: current status - Gervais/McDougall (Boston) .-Other energy sources: HIFU, inerstitial lasers, photon irradiation - Jamie Landman (New York) .-Extracoroporeal ablation: Radiosurgery - Arul Mahadevan (Cleveland) .-Practice patterns of Surgery for RCC - Brent Hollenbeck (Michigan) .-Level of evidence for NSS - Gordon Muir (London) .-NSS: Overview - Arie Belldegrun/Gill (UCLA/CCF) .-Radical nephrectomy: open - John Fitzpatrick (Dublin) .-Radical nephrectomy: laparoscopic - Clayman (Irvine) .-Cytoreductive nephrectomy: open and laparoscopic - McLellan Walther (NCI) .-Complications of radical nephrectomy: open and laparoscopic - Stuart Wolf (Michigan) .-Angio-infarction - Mark Sands (Cleveland) .-Surgery for locally advanced RCC - Chris Wood (Houston) .-Surgery for pulmonary metastases - Tom Rice (Cleveland) .-Surgery for CNS metastases - Gene Barnett (Cleveland) .-Inferior vena cava thrombi - Michael Blute (Mayo) .-Techniques for venous thrombus surgery - Mark Soloway (Miami) .-Laparoscopic techniques for venous involvement - Alireza Moinzadeh (Syracuse) .-The case for lymphadenectomy - Robert Flanigan (Loyola) .-Concomittant adrenalectomy - Seth Lerner (Houston) .-Use of transplant techniques for wide exposure of the retroperitoneum - Christian Kuhr (Seattle) .-Financial costs of renal surgery - Anoop Meraney (Cleveland) .-Level of evidence for extirpative surgery - Prokar Dasgupta (London) .-Overview of radical surgery - John Libertino (Lahey Clinic) .-Systemic metastases - ??? .-CNS disease - ?? .-Novel uses - ?? .-Surveillance after radical nephrectomy - LAM/Riggs (UCLA) .-Chemotherapy - David Nanus (Cornell) .-IFN - Bukowski, Borden (Cleveland) .-IL-2 - McDermott (Boston) .-Vaccines - Ernstoff (Dartmouth) .-Antibodies - A Jakobowitz (Agensys) .-VEGFR targeted therapy: Sorafenib - Bernard Escudier (Paris) .-VEGFR targeted therapy: Sunitinib - Bob Motzer (NYC) .-VEGF binding agents - Brian Rini (Cleveland) .-Plasma VEGF measurements, VEGF expression, response to treatment - Patard (France) .-Tor Inhibitors - Gary Hudes (Philadelphia) .-Targeted therapy & Immunotherapy combinations - Jared Gollob (Duke) .-Targeted therapy combinations - Keith Flaherty (U Penn) .-Carbonic Anhydrase IX (G250) as target for therapy - Arie Belldegrun (UCLA) .-Treatment of TKI failures - Cho/McDermott (Boston) .-Novel Agents - Bob Figlin (UCLA) .-Selection opportunities - Signoretti (Boston),Pantuck (UCLA) .-Choosing First-line therapy - Brian Rini (Cleveland) .-Treatment of Non-Clear Cell RCC - Walter Stadler (Chicago) .-Neoadjuvant therapy - Eric Jonasch (Houston) .-Adjuvant therapy: Immunotherapy - Chris Wood (Houston) .-Adjuvant therapy: Targeted therapy - Naomi Haas (Philadelphia) .-Palliative therapy - Allan Lipton (Hershey) .-Targeted therapy and Urology practice - Peter Mulder (Netherlands) .-Future directions in renal cancer - Linehan, Belldegrun, Gill, Atkins
| Erscheint lt. Verlag | 29.11.2012 |
|---|---|
| Zusatzinfo | 250 colour illustrations |
| Verlagsort | England |
| Sprache | englisch |
| Maße | 178 x 254 mm |
| Einbandart | gebunden |
| Themenwelt | Medizinische Fachgebiete ► Innere Medizin ► Nephrologie |
| Medizin / Pharmazie ► Medizinische Fachgebiete ► Onkologie | |
| ISBN-10 | 1-84882-697-4 / 1848826974 |
| ISBN-13 | 978-1-84882-697-7 / 9781848826977 |
| Zustand | Neuware |
| Informationen gemäß Produktsicherheitsverordnung (GPSR) | |
| Haben Sie eine Frage zum Produkt? |
aus dem Bereich
